Analysis of the neutrophil and platelet recovery, acute graft-versus-host disease at day 100, chronic graft-versus-host disease at 1 year, and 2-year survival of recipients of 0-3 human leukocyte antigen–mismatched umbilical cord blood versus human leukocyte antigen–matched BM
| HSC source . | N . | Neutrophil recovery d 45 . | Platelet recovery d 180 . | Grades II-IV acute GVHD . | Chronic GVHD . | 2-y survival . |
|---|---|---|---|---|---|---|
| UCB | 26 | 88% (75-100) | 72% (50-94) | 42% (23-61) | 5% (0-13) | 53% (31-75) |
| BM-MTX | 26 | 96% (89-100) | 76% (54-98) | 35% (17-53) | 20% (5-35) | 41% (22-60) |
| UCB | 31 | 85% (72-98) | 84% (64-100) | 36% (19-53) | 7% (0-16) | 52% (30-73) |
| BM-TCD | 31 | 90% (80-100) | 84% (64-100) | 35% (18-52) | 13% (1-25) | 56% (38-79) |
| HSC source . | N . | Neutrophil recovery d 45 . | Platelet recovery d 180 . | Grades II-IV acute GVHD . | Chronic GVHD . | 2-y survival . |
|---|---|---|---|---|---|---|
| UCB | 26 | 88% (75-100) | 72% (50-94) | 42% (23-61) | 5% (0-13) | 53% (31-75) |
| BM-MTX | 26 | 96% (89-100) | 76% (54-98) | 35% (17-53) | 20% (5-35) | 41% (22-60) |
| UCB | 31 | 85% (72-98) | 84% (64-100) | 36% (19-53) | 7% (0-16) | 52% (30-73) |
| BM-TCD | 31 | 90% (80-100) | 84% (64-100) | 35% (18-52) | 13% (1-25) | 56% (38-79) |
95% confidence intervals are in parentheses. All outcomes were equivalent (P > .05).
HSC indicates hematopoietic stem cell; GVHD, graft-versus-host disease; for other abbreviations, see Table 1.